Connect
← Return to Hormone Treatment Experience
Discussion
Prostate Cancer | Last Active: Jul 22, 2025 | Replies (51)
Comment receiving replies
I believe ArteraAI tells if you are likely to benefit from the addition of Abiraterone to standard ADT like Lupron or Orgovyx. It compares your cell patterns to a database of cell patterns and outcomes from past studies. From what I understand it is not definitive but another data point to be considered. But the outcome of AteraAI does not affect the decision for standard ADT.
Replies to "I believe ArteraAI tells if you are likely to benefit from the addition of Abiraterone to..."
Connect
The results of my ArteraAI test were:
"ST-ADT Biomarker: Positive. On average, patients with this result had significant risk reduction in distant metastasis with the addition short term androgen deprivation therapy."
The report itself says nothing about what type of ADT, and my RO recommended 6 months of Orgovyx, which I agreed to.
I believe you are right in how ArteraAI makes the determination.